Whitmanin
Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.
Praeklinisch / mechanistischLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Whitmanin is documented mechanistically only; no human evidence. Whitmania pigra-derived TCM preparations are NOT FDA-cleared, and whitmanin has no FDA-approved derivative.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,100 Da
- Source species
- Whitmania pigra
- Discovered
- 2018
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Zhong S et al. (2007), Biomed Chromatogr · PMID 17370295
- Zhong S et al. (2008), Zhongguo Zhong Yao Za Zhi · PMID 19260310
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.